ArticleNature protocols2016
Analysis of bacterial-surface-specific antibodies in body fluids using bacterial flow cytometry.
Article in Nature protocols, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy.Nature reviews. Clinical oncology · 2023Pooled it
- Vaginal microbe-binding antibody interactions with aMicrobiology spectrum · 2026Trial
- Multi-Mode Integrated Bioinspired Electronic Tongue for Point-of-Care Tear Diagnosis.Biosensors · 2026Article
- Transient gingival inflammation is associated with epithelial dysfunction and systemic immune activation beyond clinical improvement.Journal of periodontology · 2026Article
- A skin colonizer disrupts inflammatory and humoral immune defenses in hidradenitis suppurativa.EMBO molecular medicine · 2026Article
- Emergent spatial structure in the gut microbiota is driven by bacterial growth and gut contractions.PLoS biology · 2026Article
- Phage-steering permits antibody-mediated clearance of E. coli K1 from the gut.Nature communications · 2026Article
- Bioengineered gut bacterium synthesizing levodopa alleviates motor deficits in models of Parkinson's disease.Cell host & microbe · 2025Article
- Breast milk IgG engages the mouse neonatal immune system to instruct responses to gut antigens.Science (New York, N.Y.) · 2025Article
- Vaccine-enhanced competition permits rational bacterial strain replacement in the gut.Science (New York, N.Y.) · 2025Article
- Dielectrophoretic Microfluidic Designs for Precision Cell Enrichments and Highly Viable Label-Free Bacteria Recovery from Blood.Micromachines · 2025Article
- Article
- The level of I-FABP and IgA/IgG to beta-lactoglobulin in mothers at risk for gestational diabetes and in their children: association with antibodies toFrontiers in immunology · 2025Article
- Semisynthetic Glycoconjugate Vaccine Lead againstJournal of the American Chemical Society · 2024Article
- Article
- A Fluorinated Sialic Acid Vaccine Lead Against Meningitis B and C.Journal of the American Chemical Society · 2024Article
- Phage Immunoprecipitation Sequencing (PhIP-Seq) for Analyzing Antibody Epitope Repertoires Against Food Antigens.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Secretory-IgA binding to intestinal microbiota attenuates inflammatory reactions as the intestinal barrier of preterm infants matures.Clinical and experimental immunology · 2023Article
- Exploring Immunome and Microbiome Interplay in Reproductive Health: Current Knowledge, Challenges, and Novel Diagnostic Tools.Seminars in reproductive medicine · 2023Review
- Stability and heterogeneity in the antimicrobiota reactivity of human milk-derived immunoglobulin A.The Journal of experimental medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibacterial antibody responses that target surfaces of live bacteria or secreted toxins are likely to be relevant in controlling bacterial pathogenesis. The ability to specifically quantify bacterial-surface-binding antibodies is therefore highly attractive as a quantitative correlate of immune protection. Here, binding of antibodies from various body fluids to pure-cultured live bacteria is made visible with fluorophore-conjugated secondary antibodies and measured by flow cytometry. We indicate the necessary controls for excluding nonspecific binding and also demonstrate a cross-adsorption technique for determining the extent of cross-reactivity. This technique has numerous advantages over standard ELISA and western blotting techniques because of its independence from scaffold binding, exclusion of cross-reactive elements from lysed bacteria and ability to visualize bacterial subpopulations. In addition, less than 10(5) bacteria and less than 10 μg of antibody are required per sample. The technique requires 3-4 h of hands-on experimentation and analysis. Moreover, it can be combined with automation and mutliplexing for high-throughput applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.